NexImmune Inc.
NexImmune is a clinical-stage biotechnology company dedicated to developing innovative T cell immunotherapies using its proprietary Artificial Immune Modulation (AIM™) technology. The company focuses on harnessing natural biology to direct targeted immune responses for treating cancer, autoimmune, infectious diseases, and other conditions. With a strong leadership team, scientific advisory board, and a broad pipeline of therapies, NexImmune aims to revolutionize immunotherapy and improve patient outcomes.
Industries
Nr. of Employees
small (1-50)
NexImmune Inc.
Gaithersburg, Maryland, United States, North America
Products
Injectable antigen‑presenting nanoparticle therapeutic candidates
Biodegradable nanoparticle constructs designed for administration by direct injection or infusion to engage antigen‑specific T cells in vivo, delivering peptide–HLA recognition and co‑stimulatory signals to modulate targeted T cell populations.
Ex vivo nanoparticle‑expanded adoptive T cell therapy candidates
Ex vivo manufacturing workflows that use artificial antigen‑presenting nanoparticles to expand antigen‑specific donor‑ or patient‑derived T cells for adoptive cell therapy without genetic modification.
Platform intellectual property and peer‑reviewed evidence base
A body of peer‑reviewed publications and a multi‑jurisdictional patent portfolio supporting composition, methods, and applications of artificial antigen‑presenting nanoparticle technologies.
Injectable antigen‑presenting nanoparticle therapeutic candidates
Biodegradable nanoparticle constructs designed for administration by direct injection or infusion to engage antigen‑specific T cells in vivo, delivering peptide–HLA recognition and co‑stimulatory signals to modulate targeted T cell populations.
Ex vivo nanoparticle‑expanded adoptive T cell therapy candidates
Ex vivo manufacturing workflows that use artificial antigen‑presenting nanoparticles to expand antigen‑specific donor‑ or patient‑derived T cells for adoptive cell therapy without genetic modification.
Platform intellectual property and peer‑reviewed evidence base
A body of peer‑reviewed publications and a multi‑jurisdictional patent portfolio supporting composition, methods, and applications of artificial antigen‑presenting nanoparticle technologies.
Services
Preclinical and early clinical development for T cell immunotherapies
Discovery, translational research, and clinical program management supporting ex vivo and injectable nanoparticle‑directed T cell therapies across oncology, autoimmune, and infectious disease indications.
Process development and pilot manufacturing support for biologics and cell products
Upstream and downstream process development, scale‑up, technology transfer, pilot cGMP manufacturing runs, and preparation of technical documentation to support clinical product supply.
Preclinical and early clinical development for T cell immunotherapies
Discovery, translational research, and clinical program management supporting ex vivo and injectable nanoparticle‑directed T cell therapies across oncology, autoimmune, and infectious disease indications.
Process development and pilot manufacturing support for biologics and cell products
Upstream and downstream process development, scale‑up, technology transfer, pilot cGMP manufacturing runs, and preparation of technical documentation to support clinical product supply.
Expertise Areas
- T cell immunotherapy development
- Nanoparticle‑mediated antigen presentation
- Adoptive cell therapy manufacturing and ex vivo expansion
- Injectable nanoparticle therapeutics development
Key Technologies
- Synthetic antigen‑presenting nanoparticles
- Peptide–HLA antigen presentation systems
- Biodegradable polymer nanoparticle formulations (PLGA‑PEG)
- Ex vivo T cell enrichment and expansion platforms